Pharmaceutical compositions of posaconazole
View Patent ↗Delayed-release pharmaceutical compositions prepared by hot-melt extrusion are provided, where the compositions comprise an azole anti-fungal drug having poor water solubility, an enteric polymer and a non-enteric polymer, and wherein the pharmaceutical composition may be orally administered to a patient in either the fed or fasted state. Preferably, the delayed-release pharmaceutical compositions prepared by hot-melt extrusion comprise posaconazole, HPMC-AS and HPC. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (T max , C max , AUC 0-t and/or AUC 0-infinity ) of the azole anti-fungal drug, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.
1. A delayed-release pharmaceutical composition, comprising:
a. an intra-granular material comprising posaconazole, or a pharmaceutically acceptable salt thereof, which is molecularly dispersed in a mixture of hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) and hydroxypropyl cellulose (HPC); and
b. an extra-granular material comprising a blend of an enteric polymer and a non-enteric polymer;
wherein the extra-granular material comprises an enteric polymer selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, polyvinylacetate phthalate and mixtures thereof;
wherein the extra-granular material comprises a non-enteric polymer selected from the group consisting of polyvinylpyrrolidone, polyethylene glycol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and mixtures thereof; and
wherein the pharmaceutical composition may be administered to a patient without regard to food.
2. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a caplet, beads or granules.
3. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises from about 50 mg to about 400 mg of the posaconazole, or pharmaceutically acceptable salt thereof.
4. The delayed release composition according to claim 1 , wherein the enteric polymer in the extra-granular material comprises hydroxypropylmethyl cellulose acetate succinate (HPMC-AS).
5. The delayed release composition according to claim 1 , wherein the weight ratio in the intra-granular material of hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) to the posaconazole, or a pharmaceutically acceptable salt thereof is from 1:1 to 4:1.
6. The delayed release composition according to claim 1 , wherein the non-enteric polymer in the extra-granular material is hydroxypropyl cellulose (HPC).
7. A delayed-release pharmaceutical composition prepared by hot-melt extrusion comprising:
a. an extrudate comprising posaconazole or a pharmaceutically acceptable salt thereof, a first enteric polymer and a first non-enteric polymer; and
b. an extra-granular fraction comprising a blend of a second enteric polymer and a second non-enteric polymer,
wherein the first enteric polymer and second enteric polymer are each independently selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, polyvinylacetate phthalate and mixtures thereof;
wherein the first non-enteric polymer and second non-enteric polymer are each independently selected from the group consisting of polyvinylpyrrolidone, polyethylene glycol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and mixtures thereof; and
wherein the pharmaceutical composition may be administered to a patient without regard to food.
8. The delayed release composition according to claim 7 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a caplet, beads or granules.
9. The delayed release composition according to claim 7 , wherein the pharmaceutical composition comprises from about 50 mg to about 400 mg posaconazole, or a pharmaceutically acceptable salt thereof.
10. The delayed release composition according to claim 7 , wherein at least one of the first enteric polymer or the second enteric polymer is hydroxypropylmethyl cellulose acetate succinate (HPMC-AS).
11. The delayed release composition according to claim 7 , wherein at least one of the first non-enteric polymer or the second non-enteric polymer is hydroxypropyl cellulose (HPC).
12. The delayed release composition according to claim 7 , wherein the first enteric polymer is hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) and the first non-enteric polymer is hydroxypropyl cellulose (HPC).
13. The delayed release composition according to claim 12 , wherein the weight ratio of hydroxypropylmethyl cellulose acetate succinate to posaconazole is from 1:1 to 4:1.
14. The delayed release composition of claim 7 , wherein the pharmaceutical composition retains at least about 95% of the potency of posaconazole after storing the pharmaceutical composition at 40° C. and 75% relative humidity for at least three months.
15. A method for treatment or prevention of a fungal infection, which method comprises administering to a human a delayed-release pharmaceutical composition of claim 7 , comprising an effective amount of posaconazole or a pharmaceutically acceptable salt thereof;
wherein following oral administration of the pharmaceutical composition in the fasted state, there is no substantial difference in at least one pharmacokinetic parameter selected from the group consisting of T max , C max , AUC 0-t and AUC 0-infinity of the posaconazole, or a pharmaceutically acceptable salt thereof, as compared to the at least one pharmacokinetic parameter after oral administration in the fed state.
16. The method of claim 15 , wherein at least one pharmacokinetic parameter, subsequent to administration of the solid oral dosage form in the fasting state, is from 75% to 125% of the pharmacokinetic parameter in the fed state.
17. The method of claim 15 , wherein the area under the serum concentration versus time curve (AUC 0-inf ) of the posaconazole or a pharmaceutically acceptable salt thereof, subsequent to administration of the solid oral dosage form, is from 75% to 125% of the mean area under the posaconazole serum concentration versus time curve (AUC 0-inf ) resulting from administration of the solid oral dosage form in a fed state.
18. A process for preparing a solid oral dosage form, comprising:
a. dry-blending posaconazole, hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) and hydroxypropyl cellulose (HPC) to form a mixture,
b. heating the mixture to a temperature above the glass transition temperature (T g ) of the hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) and the hydroxypropyl cellulose (HPC), thereby forming a molten dispersion of the posaconazole in hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) and hydroxypropyl cellulose (HPC); and
c. cooling the dispersion formed in (b) to provide a composition of posaconazole in hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) and hydroxypropyl cellulose (HPC),
d. milling the composition from (c) to provide granules comprising posaconazole; and
e. mixing the granules from (d) with an extra-granular mixture comprising an enteric polymer and a non-enteric polymer to form a blend,
wherein the enteric polymer is selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, polyvinylacetate phthalate and mixtures thereof; and
wherein the non-enteric polymer is selected from the group consisting of polyvinylpyrrolidone, polyethylene glycol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and mixtures thereof.
19. The process of claim 18 , further comprising the steps of:
f. compressing the blend into tablets or filling the blend into a capsule shell; and
g. optionally, coating the tablets or capsule shell.